Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus,Journal of Thoracic Oncology

当前位置： X-MOL 学术 › J. Thorac. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus
Journal of Thoracic Oncology ( IF 20.4 ) Pub Date : 2020-02-01 , DOI: 10.1016/j.jtho.2019.09.011
Erwan Le Tallec ₁ , Alain Lescoat ₂ , Alice Ballerie ₃ , Bérengère Cador ₃ , Hervé Lena ₄ , Charles Ricordel ₄ , Sène Damien ₅ , Céleste Lebbe ₆ , Patrick Jego ₇ , Nicolas Belhomme ₈

Affiliation

Internal Medicine Department, South Hospital, Rennes, France; Rennes 1 University, Rennes, France.
Internal Medicine Department, South Hospital, Rennes, France; INSERM, Research Institute in Health, Environment, and Occupation, UMR_S 1085, Rennes 1 University, Rennes, France.
Internal Medicine Department, South Hospital, Rennes 1 University, Rennes, France, Rennes, France.
Department of Respiratory Medicine, Pontchaillou Hospital, Rennes, France; Chemistry, Oncogenesis, and Stress Signaling, INSERM U1242, Rennes 1 University, Centre Eugène Marquis, Rennes, France.
Internal Medicine Department, Lariboisière Hospital, Paris, France; INSERM UMR, Paris Diderot University, Paris, France.
Dermatology Department, AP-HP, Saint Louis Hospital, Paris, France; INSERM U976, Paris University, Paris, France.
Department of Internal Medicine, South Hospital, Rennes, France; INSERM, Research Institute in Health, Environment, and Occupation, UMR_S 1085, Rennes 1 University, Rennes, France.
Department of Internal Medicine, South Hospital, Rennes, France; Rennes 1 University, Rennes, France.

The global, randomized, double-blind, phase 3 KEYNOTE-189 study(NCT02578680) showed significantly improved OS and PFS with pembrolizumab(pembro)þpemetrexed (pem)þplatinum compared with placeboþpemþplatinumwith a manageable safety profile in pts with previously untreated metastatic nonsqua-mous NSCLC without targetable EGFR/ALK aberrationsj. We present safety and toler-ability data from Japanese pts enrolled in KEYNOTE-189

中文翻译：

纳武单抗引发的嗜酸性筋膜炎：mTOR 抑制剂西罗莫司的显着疗效

全球性、随机、双盲、3 期 KEYNOTE-189 研究 (NCT02578680) 显示，与安慰剂 + pemmouþplatinum 相比，pembrolizumab (pembro)+培美曲塞 (pem)+platinum 显着改善了 OS 和 PFS，在先前未经治疗的非转移性转移患者中具有可控的安全性无靶向 EGFR/ALK 畸变的 NSCLCj。我们提供了参加 KEYNOTE-189 的日本患者的安全性和耐受性数据

更新日期：2020-02-01

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>